B7-H7/HHLA2 hFc Chimera, Human
B7-H7/HHLA2 HFc Chimera, Human

Immobilized Human CD28H, His Tag at 5 μg /ml (100 μl/well) on the plate. Dose response curve for B7-H7/HHLA2 hFc Chimera, Human, hFc Tag with the EC50 of 90.0ng/ml determined by ELISA.

B7-H7/HHLA2 HFc Chimera, Human

The purity of B7-H7/HHLA2 hFc Chimera, Human is greater than 95% as determined by SEC-HPLC.

B7-H7/HHLA2 HFc Chimera, Human

B7-H7/HHLA2 hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

B7-H7/HHLA2 HFc Chimera, Human

B7-H7/HHLA2 hFc Chimera, Human, hFc Tag captured on CM5 Chip via Protein A can bind Human KIR3DL3, His Tag with an affinity constant of 334 nM as determined in SPR assay (Biacore T200).

B7-H7/HHLA2 hFc Chimera, Human

B7-H7, also known as HHLA2 (HERV-H LTR-associating 2), is a member of the B7 family of immune regulatory proteins.Through interaction with TMIGD2, costimulates T-cells in the context of TCR-mediated activation. Enhances T-cell proliferation and cytokine production via an AKT-dependent signaling cascade.
Z05064
¥63,425.00

Ask us a question
Product Introduction
Species Human
Protein Construction
B7-H7/HHLA2 (Ile23-Asn344)
Accession # Q9UM44-1		 hFc
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 63.7 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 78-100 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • B7-H7/HHLA2 HFc Chimera, Human
    • B7-H7/HHLA2 HFc Chimera, Human

    Immobilized Human CD28H, His Tag at 5 μg /ml (100 μl/well) on the plate. Dose response curve for B7-H7/HHLA2 hFc Chimera, Human, hFc Tag with the EC50 of 90.0ng/ml determined by ELISA.

  • B7-H7/HHLA2 HFc Chimera, Human
    • B7-H7/HHLA2 HFc Chimera, Human

    The purity of B7-H7/HHLA2 hFc Chimera, Human is greater than 95% as determined by SEC-HPLC.

  • B7-H7/HHLA2 HFc Chimera, Human
    • B7-H7/HHLA2 HFc Chimera, Human

    B7-H7/HHLA2 hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

  • B7-H7/HHLA2 HFc Chimera, Human
    • B7-H7/HHLA2 HFc Chimera, Human

    B7-H7/HHLA2 hFc Chimera, Human, hFc Tag captured on CM5 Chip via Protein A can bind Human KIR3DL3, His Tag with an affinity constant of 334 nM as determined in SPR assay (Biacore T200).


Background
Target Background B7-H7, also known as HHLA2 (HERV-H LTR-associating 2), is a member of the B7 family of immune regulatory proteins.Through interaction with TMIGD2, costimulates T-cells in the context of TCR-mediated activation. Enhances T-cell proliferation and cytokine production via an AKT-dependent signaling cascade.
Synonyms B7H7; B7-H7; HHLA2; B7 Homolog 7

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.